The April 2026 Department of Justice rescheduling order landed with the weight of a decade of advocacy behind it. For an industry that has watched every other legal sector deduct its rent, payroll, and marketing costs while cannabis operators paid taxes on money they never made, the optimism is more than justified. It is earned. The uncertainty, however, is just as real.
A Quick Reminder of Current Law
Section 280E of the Internal Revenue Code prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. Operators may deduct the cost of goods sold under §471 and nothing else. The result is effective federal tax rates of 60 to 80 percent, and in some cases well beyond, on businesses that are licensed, regulated, and paying state taxes like any other industry. Among the largest publicly traded multi-state operators, contested 280E tax liability now exceeds $1.7 billion collectively.
Why Rescheduling Moves the Needle
The statutory logic is clean. As cannabis tax attorneys have broadly noted, a completed Schedule III reclassification could eliminate 280E by its own terms, potentially improving operator profitability overnight, in some cases dramatically.
What the April Order Actually Does
Here is where the headline optimism requires a reality check. The April 23 order covers two categories: FDA-approved cannabis products and cannabis produced by operators holding a state-issued medical license. That is it (at least for now).
| Important: The April 2026 order does not broadly reschedule cannabis. Adult-use recreational operators remain in Schedule I pending completion of a formal DEA rulemaking hearing scheduled for June 29–July 15, 2026. Even for qualifying medical operators, the IRS has issued no formal guidance and is actively litigating 280E challenges in Tax Court. A final, legally durable rule covering all operators awaits the hearing, a post-hearing final rule, a likely 90-day waiting period, and near-certain legal challenges from opponents. |
What Rescheduling Doesn’t Fix
280E relief is not federal legalization. Banking access remains a legislative problem. The SAFER Banking Act is still stalled. Interstate commerce restrictions stay in place. Securities law complications for publicly traded cannabis companies don’t evaporate with a scheduling change. And state/federal conflicts don’t resolve automatically under Schedule III. The infrastructure problems that have defined this industry’s capital markets for a decade largely remain intact, unfortunately.
The Angles Worth Watching
Three questions are already moving through the industry. Will 280E relief trigger a wave of M&A activity as operators flush with new after-tax capital become acquirers? Will multi-state operators restructure entities to maximize exposure to state medical programs and capture Phase 1 relief ahead of a final rule? And will expansion plans such as new markets, facilities, and verticals that were shelved under 280E’s punishing math come back to life?
The answers are coming, but so is the litigation.
What You Can Do Now
As of April 22, 2026, state-licensed medical cannabis businesses are no longer subject to Section 280E of the Internal Revenue Code. Because the order also encourages the Treasury Department to consider retroactive 280E tax relief for prior years, a window is now open for opportunities to amend returns and file protective claims. Businesses should evaluate immediately with legal and tax counsel rather than waiting for formal guidance. The window to apply through the DEA Diversion portal for expedited DEA registration review closes on June 26, 2026. While DEA registration may not be required to obtain tax relief, it could provide important operational advantages, including the ability to transport and transact medical cannabis between DEA-registered facilities across state lines and participate more directly in medical research activities.
The Bottom Line
For operators navigating this still-unsettled landscape, 280E relief could be transformative. What hasn’t changed is the underlying risk environment: product recall exposure, business interruption vulnerability, and the coverage gaps that commercial cannabis insurance routinely leaves unaddressed. Operators who have long lacked the capital to address that exposure structurally may find, for the first time, that they have it. A captive insurance company allows an operator to turn that capital into owned, purpose-built coverage, thereby converting risk from a cost center into a financial asset.
The 280E thaw is real. In consultation with trusted counsel, applicable operators should consider the registration deadline of June 26, 2026. Plan accordingly, but verify before you act.
The post The Post-280E Opportunity: Turning Cannabis Risk Into an Asset appeared first on Cannabis Industry Journal.
